StockData
Merck & Co., Inc. logo

Merck & Co., Inc.

MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 9/30243% above fair value
$148.36−1.16 (-0.78%)

Close on Nov 2, 2026Market cap $366.03BP/E 118.7Yield 2.21%

Merck Zetia (ezetimibe, legacy pre-Organon spin-off) by Year

Zetia (ezetimibe, legacy pre-Organon spin-off) — U.S. sales ($M) ($M)

Merck Zetia (ezetimibe, legacy pre-Organon spin-off): -$1M in FY2020, down 107.1% from a year earlier. No newer figure appears in the documents we track.

Latest, FY2020
-1
Period ended Dec 31, 2020
Change on a year earlier
-107.1%
14 in FY2019
History
5 years
Since FY2016
Sources
4
Documents cited below

Where the FY2020 figure comes from

Source: Form 10-K (filed 2021-02-25) ↗

Reported in Form 10-Q / 10-K Segment & Product Sales Footnote & Form 8-K Table 3 / 3a / 3b.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedZetia (ezetimibe, legacy pre-Organon spin-off) — U.S. sales ($M) ($M)Year on yearSource
FY2020Dec 31, 2020-1-107.1%Form 10-K (filed 2021-02-25) ↗
FY2019Dec 31, 201914-68.9%Form 8-K (tm206551d1_ex99-1.htm, filed 2020-02-05) ↗
FY2018Dec 31, 201845-87.2%Form 8-K (tm206551d1_ex99-1.htm, filed 2020-02-05) ↗
FY2017Dec 31, 2017352-77.8%Form 8-K (a19-3795_1ex99d1.htm, filed 2019-02-01) ↗
FY2016Dec 31, 20161,588–Form 8-K (a18-5152_1ex99d1.htm, filed 2018-02-02) ↗

Breakdown

What makes up zetia (ezetimibe, legacy pre-Organon spin-off)

Cite this data

StockData. (2026). Merck Zetia (ezetimibe, legacy pre-Organon spin-off) ($M), annual FY2016–FY2020 [Data set]. Compiled from Merck SEC filings and investor materials. https://stockdatahq.com/stocks/mrk/kpis/rev-zetia-us

See every metric in the Merck KPI table. Data updated Oct 26, 2026.

See a number that looks wrong?